|
CN101070316A
(zh)
|
1999-04-28 |
2007-11-14 |
萨诺费－阿文蒂斯德国有限公司 |
作为ppar受体配体的二芳基酸衍生物
|
|
US6414002B1
(en)
|
1999-09-22 |
2002-07-02 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
|
|
TWI302149B
(en)
|
1999-09-22 |
2008-10-21 |
Bristol Myers Squibb Co |
Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
|
|
JP2004500389A
(ja)
*
|
2000-03-09 |
2004-01-08 |
アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Ｐｐａｒメディエーターの治療での使用
|
|
JP2001261654A
(ja)
*
|
2000-03-21 |
2001-09-26 |
Mitsui Chemicals Inc |
キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬
|
|
AU2002215218A1
(en)
*
|
2000-11-17 |
2002-05-27 |
Takeda Chemical Industries Ltd. |
Isoxazole derivatives
|
|
GB0029974D0
(en)
|
2000-12-08 |
2001-01-24 |
Glaxo Group Ltd |
Chemical compounds
|
|
CA2433573A1
(en)
|
2000-12-28 |
2002-07-11 |
Takeda Chemical Industries, Ltd. |
Alkanoic acid derivatives, process for their production and use thereof
|
|
WO2002064632A2
(en)
*
|
2001-02-01 |
2002-08-22 |
Smithkline Beecham Corporation |
Crystallized ppar$g(a) ligand binding domain polypeptide and screening methods employing same
|
|
US7241785B2
(en)
|
2001-03-23 |
2007-07-10 |
Takeda Pharmaceutical Company Limited |
Five-membered heterocyclic alkanoic acid derivative
|
|
US7253178B2
(en)
|
2001-03-28 |
2007-08-07 |
Eisai Co., Ltd. |
Carboxylic acids
|
|
WO2002081428A1
(fr)
|
2001-03-30 |
2002-10-17 |
Eisai Co., Ltd. |
Compose de benzene et sel de ce compose
|
|
TWI311133B
(en)
*
|
2001-04-20 |
2009-06-21 |
Eisai R&D Man Co Ltd |
Carboxylic acid derivativeand the salt thereof
|
|
US20030092736A1
(en)
*
|
2001-05-30 |
2003-05-15 |
Cheng Peter T. |
Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
|
|
GB0113231D0
(en)
|
2001-05-31 |
2001-07-25 |
Glaxo Group Ltd |
Chemical compounds
|
|
WO2002098840A1
(fr)
*
|
2001-06-04 |
2002-12-12 |
Eisai Co., Ltd. |
Derive de l'acide carboxylique et medicament comprenant un sel ou un ester dudit derive
|
|
EP1397130B1
(en)
|
2001-06-20 |
2007-07-25 |
Wyeth |
Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
|
TWI224101B
(en)
|
2001-06-20 |
2004-11-21 |
Wyeth Corp |
Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
|
|
AR036237A1
(es)
|
2001-07-27 |
2004-08-25 |
Bayer Corp |
Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
|
|
US20110065129A1
(en)
|
2001-07-27 |
2011-03-17 |
Lowe Derek B |
Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
|
|
ATE381542T1
(de)
*
|
2001-08-13 |
2008-01-15 |
Phenex Pharmaceuticals Ag |
Nr1h4-kern-rezeptor-bindende verbindungen
|
|
US7371777B2
(en)
|
2001-08-17 |
2008-05-13 |
Eisai Co., Ltd. |
Cyclic compound and PPAR agonist
|
|
KR100915108B1
(ko)
|
2001-08-31 |
2009-09-03 |
사노피-아벤티스 도이칠란트 게엠베하 |
Ｐｐａｒ-활성화제로서의 디아릴사이클로알킬 유도체 및 이를 포함하는 약제학적 조성물
|
|
US6884812B2
(en)
|
2001-08-31 |
2005-04-26 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
|
|
US7399777B2
(en)
|
2001-08-31 |
2008-07-15 |
Sanofi-Aventis Deutschland Gmbh |
Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
|
|
US6716842B2
(en)
|
2002-04-05 |
2004-04-06 |
Warner-Lambert Company, Llc |
Antidiabetic agents
|
|
US7078404B2
(en)
|
2002-04-11 |
2006-07-18 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-3-carboxyphenylurea derivatives, processes for preparing them and their use
|
|
US7223796B2
(en)
|
2002-04-11 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
|
|
CA2487315A1
(en)
*
|
2002-05-24 |
2003-12-04 |
Takeda Pharmaceutical Company Limited |
1,2-azole derivatives with hypoglycemic and hypolipidemic activity
|
|
JP2004277397A
(ja)
*
|
2002-05-24 |
2004-10-07 |
Takeda Chem Ind Ltd |
１，２−アゾール誘導体
|
|
US7049341B2
(en)
|
2002-06-07 |
2006-05-23 |
Aventis Pharma Deutschland Gmbh |
N-benzoylureidocinnamic acid derivatives, processes for preparing them and their use
|
|
GB0214149D0
(en)
*
|
2002-06-19 |
2002-07-31 |
Glaxo Group Ltd |
Chemical compounds
|
|
SE0201937D0
(sv)
|
2002-06-20 |
2002-06-20 |
Astrazeneca Ab |
Therapeutic agents
|
|
ATE386013T1
(de)
|
2002-06-20 |
2008-03-15 |
Astrazeneca Ab |
Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz
|
|
US7351858B2
(en)
|
2002-06-20 |
2008-04-01 |
Astrazeneca Ab |
Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
|
|
EP1656368A4
(en)
|
2002-07-09 |
2009-08-26 |
Bristol Myers Squibb Co |
SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AGENTS AND ANTIABESITY AND THEIR MANUFACTURING PROCESS
|
|
WO2004007439A1
(ja)
*
|
2002-07-10 |
2004-01-22 |
Sumitomo Pharmaceuticals Co., Ltd. |
ビアリール誘導体
|
|
US7262220B2
(en)
|
2002-07-11 |
2007-08-28 |
Sanofi-Aventis Deutschland Gmbh |
Urea- and urethane-substituted acylureas, process for their preparation and their use
|
|
DE10231370B4
(de)
|
2002-07-11 |
2006-04-06 |
Sanofi-Aventis Deutschland Gmbh |
Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
|
JP2006502247A
(ja)
|
2002-07-12 |
2006-01-19 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
複素環で置換されたベンゾイル尿素、その製造方法および医薬としてのその使用
|
|
DE60332738D1
(de)
*
|
2002-07-30 |
2010-07-08 |
Merck Sharp & Dohme |
Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
|
|
JP2004123732A
(ja)
*
|
2002-09-10 |
2004-04-22 |
Takeda Chem Ind Ltd |
５員複素環化合物
|
|
US7368578B2
(en)
|
2002-09-10 |
2008-05-06 |
Takeda Pharmaceutical Company Limited |
Five-membered heterocyclic compounds
|
|
US20040157922A1
(en)
|
2002-10-04 |
2004-08-12 |
Aventis Pharma Deutschland Gmbh |
Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
|
|
US7208504B2
(en)
|
2002-10-12 |
2007-04-24 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic inhibitors of hormone sensitive lipase
|
|
EP2385032A1
(en)
|
2002-11-08 |
2011-11-09 |
Takeda Pharmaceutical Company Limited |
GPR40 Receptor function regulator
|
|
WO2004048349A1
(en)
|
2002-11-22 |
2004-06-10 |
Smithkline Beecham Corporation |
Farnesoid x receptor agonists
|
|
ES2268480T3
(es)
|
2002-12-10 |
2007-03-16 |
Wyeth |
Derivados del acido 3-alquilo- y 3-arilalquilo-1h-indol-1-il-acetico sustituidos como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1).
|
|
AU2003297787A1
(en)
|
2002-12-10 |
2004-06-30 |
Wyeth |
Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
|
BR0316585A
(pt)
|
2002-12-10 |
2005-10-04 |
Wyeth Corp |
Derivados de ácido glioxìlico aril, ariloxi e alquiloxi 1h-indol-3-il substituìdos como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
|
|
UA80453C2
(en)
|
2002-12-10 |
2007-09-25 |
|
Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
|
|
DE10258007B4
(de)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
|
US6653334B1
(en)
*
|
2002-12-27 |
2003-11-25 |
Kowa Co., Ltd. |
Benzoxazole compound and pharmaceutical composition containing the same
|
|
CA2509202A1
(en)
|
2003-01-06 |
2004-07-29 |
Eli Lilly And Company |
Fused heterocyclic derivatives as ppar modulators
|
|
US20040242583A1
(en)
|
2003-01-20 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
|
|
US7179941B2
(en)
|
2003-01-23 |
2007-02-20 |
Sanofi-Aventis Deutschland Gmbh |
Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
|
|
US7196114B2
(en)
|
2003-02-17 |
2007-03-27 |
Sanofi-Aventis Deutschland Gmbh |
Substituted 3-(benzoylureido) thiophene derivatives, processes for preparing them and their use
|
|
DE10308352A1
(de)
|
2003-02-27 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
|
DE10308351A1
(de)
*
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
DE10308354A1
(de)
*
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
US7148246B2
(en)
|
2003-02-27 |
2006-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
|
|
DE10308355A1
(de)
*
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
|
DE10308350B4
(de)
*
|
2003-02-27 |
2006-06-01 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 1,3-Cyclohexandiol-Derivaten
|
|
DE10308353A1
(de)
*
|
2003-02-27 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
US7501440B2
(en)
|
2003-03-07 |
2009-03-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
|
|
DE10313228A1
(de)
*
|
2003-03-25 |
2004-10-21 |
Aventis Pharma Deutschland Gmbh |
Synthese von 2-Chlormethyl-6-methylbenzoesäureestern
|
|
US6989462B2
(en)
|
2003-03-25 |
2006-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Synthesis of 2-chloromethyl-6-methylbenzoic ester
|
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
|
US7244763B2
(en)
*
|
2003-04-17 |
2007-07-17 |
Warner Lambert Company Llc |
Compounds that modulate PPAR activity and methods of preparation
|
|
EP1630152A4
(en)
|
2003-05-30 |
2009-09-23 |
Takeda Pharmaceutical |
CONNECTION WITH CONDENSED RING
|
|
US7202266B2
(en)
|
2003-07-17 |
2007-04-10 |
Plexxikon, Inc. |
PPAR active compounds
|
|
US7348338B2
(en)
|
2003-07-17 |
2008-03-25 |
Plexxikon, Inc. |
PPAR active compounds
|
|
US7008957B2
(en)
|
2003-07-25 |
2006-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
|
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
|
WO2005016240A2
(en)
*
|
2003-08-01 |
2005-02-24 |
Nobex Corporation |
Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same
|
|
DE10335450A1
(de)
*
|
2003-08-02 |
2005-02-17 |
Bayer Ag |
Indolin-Sulfanilsäureamide
|
|
WO2005012221A1
(ja)
*
|
2003-08-04 |
2005-02-10 |
Ono Pharmaceutical Co., Ltd. |
ジフェニルエーテル化合物、その製造方法および用途
|
|
AU2004268839A1
(en)
|
2003-09-03 |
2005-03-10 |
Pfizer Inc. |
Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists
|
|
CN100482649C
(zh)
*
|
2003-09-17 |
2009-04-29 |
诺瓦提斯公司 |
有机化合物
|
|
US7442805B2
(en)
|
2003-09-25 |
2008-10-28 |
Wyeth |
Substituted sulfonamide-indoles
|
|
US7332521B2
(en)
|
2003-09-25 |
2008-02-19 |
Wyeth |
Substituted indoles
|
|
US7268159B2
(en)
|
2003-09-25 |
2007-09-11 |
Wyeth |
Substituted indoles
|
|
US7351726B2
(en)
|
2003-09-25 |
2008-04-01 |
Wyeth |
Substituted oxadiazolidinediones
|
|
US7411083B2
(en)
|
2003-09-25 |
2008-08-12 |
Wyeth |
Substituted acetic acid derivatives
|
|
US7141592B2
(en)
|
2003-09-25 |
2006-11-28 |
Wyeth |
Substituted oxadiazolidinediones
|
|
US7163954B2
(en)
|
2003-09-25 |
2007-01-16 |
Wyeth |
Substituted naphthyl benzothiophene acids
|
|
US7582773B2
(en)
|
2003-09-25 |
2009-09-01 |
Wyeth |
Substituted phenyl indoles
|
|
US7446201B2
(en)
|
2003-09-25 |
2008-11-04 |
Wyeth |
Substituted heteroaryl benzofuran acids
|
|
JP2007527416A
(ja)
|
2003-10-31 |
2007-09-27 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ペルオキシソーム増殖因子活性化受容体（ｐｐａｒ）二重作動薬として有用なフェノキシ酢酸誘導体
|
|
EP1689383B1
(en)
|
2003-11-19 |
2012-10-31 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
|
JP4922615B2
(ja)
|
2003-11-26 |
2012-04-25 |
武田薬品工業株式会社 |
受容体機能調節剤
|
|
DE10360525B3
(de)
*
|
2003-12-22 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Verfahren zur Herstellung von substituierten 2-(Phenoxymethyl)-benzoesäuren
|
|
US7238835B2
(en)
|
2003-12-22 |
2007-07-03 |
Sanofi-Aventis Deutschland Gmbh |
Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids
|
|
EP1697339A1
(en)
|
2003-12-25 |
2006-09-06 |
Takeda Pharmaceutical Company Limited |
3-(4-benzyloxyphenyl)propanoic acid derivatives
|
|
JP4855777B2
(ja)
*
|
2003-12-26 |
2012-01-18 |
武田薬品工業株式会社 |
フェニルプロパン酸誘導体
|
|
US7470706B2
(en)
|
2004-01-31 |
2008-12-30 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
|
US7498341B2
(en)
|
2004-01-31 |
2009-03-03 |
Sanofi Aventis Deutschland Gmbh |
Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
|
|
DE102004005172A1
(de)
|
2004-02-02 |
2005-08-18 |
Aventis Pharma Deutschland Gmbh |
Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
|
|
BRPI0508098A
(pt)
|
2004-02-27 |
2007-07-17 |
Amgen Inc |
compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
|
|
EP1586573B1
(en)
|
2004-04-01 |
2007-02-07 |
Sanofi-Aventis Deutschland GmbH |
Oxadiazolones, processes for their preparation and their use as pharmaceuticals
|
|
US7625949B2
(en)
|
2004-04-23 |
2009-12-01 |
Roche Palo Alto Llc |
Methods for treating retroviral infections
|
|
US7166738B2
(en)
|
2004-04-23 |
2007-01-23 |
Roche Palo Alto Llc |
Non-nucleoside reverse transcriptase inhibitors
|
|
CA2572872C
(en)
*
|
2004-07-02 |
2013-10-22 |
Sankyo Company Limited |
Tissue factor production inhibitor
|
|
BRPI0515015A
(pt)
|
2004-08-11 |
2008-07-01 |
Kyorin Seiyaku Kk |
derivado cìclico de ácido aminobenzóico; medicamento; agonista ppar(alpha); agonista duplo ppar(alpha), y; agonista duplo ppar(alpha), (delta); modulador ppar; agente lipìdeo; agente profilático ou terapêutico compreendendo pelo menos um dos derivados cìclicos de ácido aminobenzóico ou sal do mesmo farmacêuticamente aceitável
|
|
DE102004039509B4
(de)
|
2004-08-14 |
2006-09-21 |
Sanofi-Aventis Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
JP2008510815A
(ja)
|
2004-08-23 |
2008-04-10 |
ワイス |
血栓症および心臓血管疾患の治療にて有用な調節剤であるプラスミノゲン活性化因子阻害剤１型（ｐａｉ−１）としてのオキサゾロ−ナフチル酸
|
|
ATE425158T1
(de)
*
|
2004-10-18 |
2009-03-15 |
Merck & Co Inc |
Diphenyl-substituierte alkane als flap- inhibitoren
|
|
US7923573B2
(en)
|
2004-10-27 |
2011-04-12 |
Daiichi Sankyo Company, Limited |
Benzene compound having 2 or more substituents
|
|
WO2006057448A1
(ja)
*
|
2004-11-26 |
2006-06-01 |
Takeda Pharmaceutical Company Limited |
アリールアルカン酸誘導体
|
|
US7531568B2
(en)
|
2004-11-30 |
2009-05-12 |
Plexxikon, Inc. |
PPAR active compounds
|
|
CA2600074A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Kyorin Pharmaceutical Co., Ltd. |
Novel cyclic aminophenylalkanoic acid derivative
|
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
|
BRPI0614340A2
(pt)
|
2005-08-17 |
2011-04-12 |
Wyeth Corp |
indóis substituìdos e métodos de seu uso
|
|
RU2008108221A
(ru)
*
|
2005-09-07 |
2009-10-20 |
Плекссикон, Инк. (Us) |
Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом)
|
|
BRPI0617207A2
(pt)
|
2005-09-29 |
2011-07-19 |
Sanofi Aventis |
derivados de fenil-1,2,4-oxadiazolona, processos para sua preparação e seu uso como produtos farmacêuticos
|
|
AU2006303368B2
(en)
|
2005-10-19 |
2011-05-26 |
F. Hoffmann-La Roche Ag |
Non-Nucleoside Reverse Transcriptase Inhibitors
|
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
|
PE20080993A1
(es)
|
2006-06-27 |
2008-10-06 |
Takeda Pharmaceutical |
Compuestos ciclicos fusionados como moduladores del receptor gpr40
|
|
WO2008035306A1
(en)
*
|
2006-09-21 |
2008-03-27 |
Piramal Life Sciences Limited |
3 -amino- pyridine derivatives for the treatment of metabolic disorders
|
|
DE102007002260A1
(de)
|
2007-01-16 |
2008-07-31 |
Sanofi-Aventis |
Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
|
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
|
AU2008221673B2
(en)
*
|
2007-03-08 |
2013-03-28 |
Albireo Ab |
2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
|
|
PE20090159A1
(es)
|
2007-03-08 |
2009-02-21 |
Plexxikon Inc |
COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
|
|
BRPI0701664A2
(pt)
*
|
2007-05-28 |
2009-01-13 |
Fundacao Universidade Fed De Sco Carlos |
4-quinolinonas e quinolinas, processo de preparaÇço, formulaÇÕes farmacÊuticas e uso das mesmas
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
CN101381302B
(zh)
*
|
2007-09-07 |
2013-04-03 |
上海睿智化学研究有限公司 |
2-溴甲基-6-甲基苯甲酰氯/溴的制备方法
|
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
|
DE102007063671A1
(de)
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
|
WO2009078981A2
(en)
*
|
2007-12-13 |
2009-06-25 |
Sri International |
Ppar-delta ligands and methods of their use
|
|
JP2011506445A
(ja)
*
|
2007-12-13 |
2011-03-03 |
アムジエン・インコーポレーテツド |
γ−セクレターゼ調節剤
|
|
MX2010008260A
(es)
|
2008-02-01 |
2010-12-20 |
Amira Pharmaceuticals Inc |
Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina.
|
|
JP2011512359A
(ja)
*
|
2008-02-14 |
2011-04-21 |
アミラ ファーマシューティカルズ，インク． |
プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
|
|
EP2245022A4
(en)
|
2008-02-25 |
2012-02-22 |
Panmira Pharmaceuticals Llc |
ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
|
|
JP2011518130A
(ja)
*
|
2008-04-02 |
2011-06-23 |
アミラ ファーマシューティカルズ，インク． |
プロスタグランジンｄ２受容体のアミノアルキルフェニルアンタゴニスト
|
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
|
DE102008018675A1
(de)
*
|
2008-04-14 |
2009-10-15 |
Bayer Schering Pharma Aktiengesellschaft |
Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung
|
|
KR101325367B1
(ko)
*
|
2008-07-03 |
2013-11-11 |
판미라 파마슈티칼스, 엘엘씨 |
프로스타글란딘 ｄ２ 수용체의 길항제
|
|
WO2010003624A2
(en)
|
2008-07-09 |
2010-01-14 |
Sanofi-Aventis |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
|
EP2317845A4
(en)
|
2008-07-18 |
2011-11-09 |
Zafgen Inc |
METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON
|
|
US8378107B2
(en)
|
2008-10-01 |
2013-02-19 |
Panmira Pharmaceuticals, Llc |
Heteroaryl antagonists of prostaglandin D2 receptors
|
|
US8524748B2
(en)
|
2008-10-08 |
2013-09-03 |
Panmira Pharmaceuticals, Llc |
Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
|
|
WO2010057118A2
(en)
|
2008-11-17 |
2010-05-20 |
Amira Pharmaceuticals, Inc. |
Heterocyclic antagonists of prostaglandin d2 receptors
|
|
WO2010065883A2
(en)
|
2008-12-04 |
2010-06-10 |
Zafgen Corporation |
Method of treating an overweight or obese subject
|
|
US20120004162A1
(en)
|
2008-12-04 |
2012-01-05 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
|
US20100173313A1
(en)
*
|
2009-01-08 |
2010-07-08 |
Amira Pharmaceuticals, Inc. |
Biomarkers of inflammation
|
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
|
KR20120026612A
(ko)
|
2009-06-09 |
2012-03-19 |
아브락시스 바이오사이언스, 엘엘씨 |
벤질 치환 트리아진 유도체와 이들의 치료적 용도
|
|
CA2765030C
(en)
|
2009-06-09 |
2015-10-27 |
California Capital Equity, Llc |
Triazine derivatives and their therapeutical applications
|
|
CN102573473B
(zh)
|
2009-06-09 |
2015-05-27 |
加利福尼亚资本权益有限责任公司 |
用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物
|
|
EP2462110A4
(en)
*
|
2009-08-05 |
2013-04-03 |
Panmira Pharmaceuticals Llc |
DP2 ANTAGONIST AND USES THEREOF
|
|
RU2012111354A
(ru)
|
2009-08-26 |
2013-10-10 |
Санофи |
Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование
|
|
AU2010302642A1
(en)
|
2009-10-02 |
2012-04-26 |
Sanofi |
Use of compounds with SGLT-1/SGLT-2 inhibitor activity for producing medicaments for treatment of bone diseases
|
|
MX337575B
(es)
*
|
2009-10-09 |
2016-03-10 |
Zafgen Corp |
Compuestos de sulfona y métodos para lafabricación y uso de éstos.
|
|
DE102009046115A1
(de)
|
2009-10-28 |
2011-09-08 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte 3-Phenylpropansäuren und ihre Verwendung
|
|
EP2521713A4
(en)
|
2010-01-06 |
2013-10-02 |
Panmira Pharmaceuticals Llc |
ANTAGONIST OF DP2 AND ITS USES
|
|
US8815309B2
(en)
|
2010-01-08 |
2014-08-26 |
Zafgen, Inc. |
Methods of treating a subject with benign prostate hyperplasia
|
|
WO2011085201A1
(en)
|
2010-01-08 |
2011-07-14 |
Zafgen Corporation |
Fumagillol type compounds and methods of making and using same
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US20130266578A1
(en)
|
2010-04-07 |
2013-10-10 |
Thomas E. Hughes |
Methods of treating an overweight subject
|
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
CA2804593C
(en)
|
2010-07-09 |
2015-11-24 |
Pfizer Limited |
Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
|
|
CA2804877A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
|
|
JP2013532184A
(ja)
|
2010-07-12 |
2013-08-15 |
ファイザー・リミテッド |
電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
|
|
EP2593433B1
(en)
|
2010-07-12 |
2014-11-26 |
Pfizer Limited |
N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
|
|
WO2012007868A2
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
|
CA2800971A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
|
EP2595988B1
(en)
|
2010-07-22 |
2014-12-17 |
Zafgen, Inc. |
Tricyclic compounds and methds of making and using same
|
|
UA111479C2
(ru)
|
2010-11-09 |
2016-05-10 |
Зафджен, Інк. |
Кристаллические формы ингибитора metap-2 и способы их получения и применения
|
|
US9173865B2
(en)
|
2010-11-29 |
2015-11-03 |
Zafgen, Inc. |
Treatment of obesity using non-daily administration of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol
|
|
KR20130136504A
(ko)
|
2010-12-07 |
2013-12-12 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
치환된 1-벤질사이클로알킬카르복실산 및 그의 용도
|
|
NZ611529A
(en)
|
2010-12-23 |
2015-06-26 |
Pfizer |
Glucagon receptor modulators
|
|
CA2825408A1
(en)
|
2011-01-26 |
2012-08-02 |
Zafgen, Inc. |
Tetrazole compounds and methods of making and using same
|
|
ME02502B
(me)
|
2011-02-08 |
2017-02-20 |
Pfizer |
Modulator glukagonskog receptora
|
|
US8901114B2
(en)
|
2011-03-08 |
2014-12-02 |
Sanofi |
Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
|
|
WO2012120056A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120053A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120055A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683705B1
(de)
|
2011-03-08 |
2015-04-22 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
JP5876513B2
(ja)
|
2011-03-08 |
2016-03-02 |
ザフゲン，インコーポレイテッド |
オキサスピロ［２．５］オクタン誘導体および類似体
|
|
DE102011007272A1
(de)
|
2011-04-13 |
2012-10-18 |
Bayer Pharma Aktiengesellschaft |
Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
|
|
WO2012154678A1
(en)
|
2011-05-06 |
2012-11-15 |
Zafgen Corporation |
Tricyclic sulfonamide compounds and methods of making and using same
|
|
JP6062423B2
(ja)
|
2011-05-06 |
2017-01-18 |
ザフゲン，インコーポレイテッド |
部分飽和三環式化合物ならびにその製造および使用方法
|
|
BR112013028666A2
(pt)
|
2011-05-06 |
2017-08-08 |
Zafgen Inc |
compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
|
|
JP5647379B2
(ja)
|
2011-07-22 |
2014-12-24 |
ファイザー・インク |
キノリニルグルカゴン受容体モジュレーター
|
|
JP2014525932A
(ja)
|
2011-08-15 |
2014-10-02 |
インターミューン， インコーポレイテッド |
リゾホスファチド酸レセプターアンタゴニスト
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2763671A2
(en)
|
2011-10-03 |
2014-08-13 |
Zafgen, Inc. |
Methods of treating age related disorders
|
|
JP2015509102A
(ja)
|
2012-01-18 |
2015-03-26 |
ザフゲン，インコーポレイテッド |
三環式スルホン化合物並びにその作製および使用方法
|
|
CA2861390A1
(en)
|
2012-01-18 |
2013-07-25 |
Zafgen, Inc. |
Tricyclic sulfonamide compounds and methods of making and using same
|
|
KR20150016303A
(ko)
|
2012-05-07 |
2015-02-11 |
자프겐 인크. |
6-o-(4-디메틸아미노에톡시) 신나모일 푸마지롤의 옥살레이트 염의 다형체 염 및 이의 제조 및 사용 방법
|
|
KR20150013222A
(ko)
|
2012-05-08 |
2015-02-04 |
자프겐 인크. |
Metap2 저해제를 이용한 시상하부 비만의 치료
|
|
CN104364251B
(zh)
|
2012-05-09 |
2017-02-22 |
扎夫根股份有限公司 |
烟曲霉醇型化合物及其制备和使用方法
|
|
DE102012208530A1
(de)
|
2012-05-22 |
2013-11-28 |
Bayer Pharma AG |
Substituierte Piperidinoacetamide und ihre Verwendung
|
|
JP2015536981A
(ja)
|
2012-11-05 |
2015-12-24 |
ザフゲン，インコーポレイテッド |
三環式化合物ならびにその製造および使用方法
|
|
AU2013337288A1
(en)
|
2012-11-05 |
2015-05-21 |
Zafgen, Inc. |
Tricyclic compounds for use in the treatment and/or control of obesity
|
|
NZ707773A
(en)
|
2012-11-05 |
2019-05-31 |
Zafgen Inc |
Methods of treating liver diseases
|
|
KR20150126924A
(ko)
|
2013-03-14 |
2015-11-13 |
자프겐 인크. |
신장 질환 및 기타 장애의 치료 방법
|
|
SG11201507320QA
(en)
|
2013-03-15 |
2015-10-29 |
Global Blood Therapeutics Inc |
Compounds and uses thereof for the modulation of hemoglobin
|
|
RU2671496C2
(ru)
|
2013-10-14 |
2018-11-01 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Производные 5-пиперидин-8-цианохинолина
|
|
CN110105346B
(zh)
|
2013-10-14 |
2023-03-10 |
卫材R&D管理有限公司 |
选择性取代的喹啉化合物
|
|
EA202092627A1
(ru)
|
2013-11-18 |
2021-09-30 |
Глобал Блад Терапьютикс, Инк. |
Соединения и их применения для модуляции гемоглобина
|
|
JP6699011B2
(ja)
*
|
2014-07-04 |
2020-05-27 |
国立大学法人 東京大学 |
脂肪酸サロゲートを含むリゾホスファチジルセリン誘導体
|
|
EP2982667A1
(en)
|
2014-08-04 |
2016-02-10 |
Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. |
Competitive PPAR-gamma antagonists
|
|
WO2016055792A1
(en)
|
2014-10-10 |
2016-04-14 |
Pulmocide Limited |
Novel 5,6-dihydro-4h-benzo[b]thieno-[2,3-d]azepine derivatives
|
|
JP6694886B2
(ja)
|
2014-12-18 |
2020-05-20 |
プルモシデ リミテド |
４，５−ジヒドロ−６Ｈ−チエノ［３，２−ｄ］ベンゾアゼピン誘導体及び呼吸器合胞体ウイルス（ＲＳＶ）感染を治療するためのその使用
|
|
KR20170098869A
(ko)
|
2014-12-18 |
2017-08-30 |
바이엘 파마 악티엔게젤샤프트 |
치환된 피리딜-시클로알킬-카르복실산, 그를 함유하는 조성물 및 그의 의학적 용도
|
|
AR105671A1
(es)
|
2015-08-11 |
2017-10-25 |
Zafgen Inc |
Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
|
|
CN106432255A
(zh)
|
2015-08-11 |
2017-02-22 |
扎夫根公司 |
烟曲霉素醇螺环化合物和制备和使用其的方法
|
|
TN2020000001A1
(en)
|
2017-07-11 |
2021-10-04 |
Vertex Pharma |
Carboxamides as modulators of sodium channels
|
|
US11612580B2
(en)
|
2017-10-16 |
2023-03-28 |
The Board Of Regents Of The University Of Texas System |
Compositions for inhibiting 3′ repair exonuclease 2 and methods of screening for such compositions
|
|
US10905667B2
(en)
|
2018-07-24 |
2021-02-02 |
Bayer Pharma Aktiengesellschaft |
Orally administrable modified-release pharmaceutical dosage form
|
|
CA3164134A1
(en)
|
2019-12-06 |
2021-06-10 |
Vertex Pharmaceuticals Incorporated |
Substituted tetrahydrofurans as modulators of sodium channels
|
|
CA3221259A1
(en)
|
2021-06-04 |
2022-12-08 |
Vertex Pharmaceuticals Incorporated |
N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
|
|
WO2024039864A1
(en)
*
|
2022-08-19 |
2024-02-22 |
Purdue Research Foundation |
Protein:protein interaction inhibitors
|